Key Highlights:
- Granules India plans to invest ~₹2,000 crore over the next 3–4 years, targeting complex generics, oncology, peptide CDMO, US operations, manufacturing capacity, R&D, digitalisation, AI-led manufacturing and quality systems.
- The company is shifting from volume-led generics toward higher-value products, with complex generics rising from 1% of revenue in FY20 to 33% in FY26. Its four growth engines are controlled substances, complex generics, oncology and peptide CDMO.
- Granules has also filed two sole first-to-file ANDAs for generic Lumryz and Dyanavel, targeting a combined US market of >$350M and potential 180-day exclusivity. Its peptide CDMO business is targeting $50M revenue in three years and >$100M within five years.
Implications:
Granules India’s ₹2,000 crore investment signals an aggressive shift toward higher-margin, complex generics, oncology and peptide CDMO, reducing reliance on commoditized generics. First-to-file opportunities and targeted US expansion could strengthen its competitive position, while intensifying competition in specialized generics and outsourced peptide manufacturing.
Source: ET Pharma
